The study of the usefulness of beta-blocker for hypertensive patients with persistent atrial fibrillation combined with reduced cardiac functio
Not Applicable
Recruiting
- Conditions
- hypertensive patients with persistent atrial fibrillation combined with reduced cardiac function
- Registration Number
- JPRN-UMIN000001848
- Lead Sponsor
- ihon University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with class III or IV of NYHA classification
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Subjective symptom: Frequency of palpitation 2. Objective symptom: New York Heart Association (NYHA) classification of cardiac performance, BP, HR 3. Laboratory test: Blood biochemical findings include BNP, NT-proBNP, Urinalysis 4. Physiological laboratory: ambulatory electrocardiography, cardiac ultrasonography 5. Adverse event
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie beta-blocker efficacy in hypertensive patients with persistent atrial fibrillation and reduced cardiac function?
How do beta-blockers compare to standard-of-care treatments for managing hypertension in patients with persistent atrial fibrillation and reduced cardiac function?
Which biomarkers are associated with improved outcomes in hypertensive patients with persistent atrial fibrillation and reduced cardiac function treated with beta-blockers?
What adverse events are commonly observed in beta-blocker therapy for patients with persistent atrial fibrillation and reduced cardiac function?
Are there any combination therapies or alternative drugs that enhance beta-blocker effectiveness in managing hypertension and atrial fibrillation with reduced cardiac function?